User:Bwiesnoski/sandbox

''"ANI Pharmaceuticals, inc." ''In an American pharmaceuticals company that is an emerging leader in the specialty pharmaceuticals market. the company is involved in every stage of pharmaceutical production which includes development, manufacturing, and marketing prescription drugs.The company is headquartered in Baudette, Minnesota and has manufacturing facilities in Baudette and Gulfport, Mississippi.

Up until 2007 ANI was only a holding company, and did not develop or produce any products. In 2007 the company acquired a number of production and development facilities, and subsequently began producing it's own prescription drugs. ANI currently markets and produces a number of different products for female sexual health, menopause, contraception and male hypogonadism. In 2012 ANI completed a merger with BioSante Pharmaceuticals, and continued under the under the name ANI.

History
ANI Pharmaceuticals was initially started 2001 in Baudette, Minnesota under the name ASHCO. Initially the company was not involved in the production of prescription drugs, but rather was just a holding company for other drug companies. During this time ANI was a subsidiary of Bactolac Pharmaceuticals. In 2007 ASHCO changed its name to ANI after Bactolac divested in the company. At this time ANI purchased the facilities necessary to research and produce their own line of prescription drugs. ANI purchased two facilities in order to be able to produce its own line of drugs. These state of the art facilities are a combined 170,000 square feet and contained ANI's manufacturing, packaging, drug production, and extensive research operations. The first facility that ANI purchased is located near company headquarters in Baudette, while the other is located in Gulfport, Mississippi. In addition to manufacturing their own line of prescription drugs ANI began contracting manufacturing drugs for other companies after acquiring their production facilities. ANI continues to own and operate these facilities to this day.

Products
ANI produces a number of of FDA approved prescription drugs that treat a variety of ailments. The company sell its products to a number of larger and medium distributors along with multiple smaller distributors. In addition to selling their product to distributors ANI sells their drugs directly to major pharmacies and retail outlets. In addition to producing drugs that are privately labeled ANI produces a number of brand name drugs with broad applications. ANI produces products that are used in enemas, promote female sexual health, are used for contraception, and treat hypogonadism. The majority of the products that ANI produces are testosterones used to treat a number of different sexually related ailments. in addition to the products that ANI currently produces they have number of products that they are in development or are currently awaiting approval by the FDA, and the company expects to increase their product line in the coming years.

Merger
In October of 2012 ANI Pharmaceuticals merged with BIoSante Pharmaceuticals inc. Although there were a number of different reasons for this merger BioSante's cash reserve played a major role. The merger allowed ANI access to BioSante's cash for development of new and existing products. BioSante wished to Merge with ANI because of the the unique private label and branded prescription drugs that ANI produces. By merging the two companies wish to increase value for their shareholders and foster new development.